<DOC>
	<DOCNO>NCT00741169</DOCNO>
	<brief_summary>The purpose study assess interaction see somebody dose TMC435350 Rifampin ( commercial form antibiotic ) .</brief_summary>
	<brief_title>TMC435350-TiDP16-C105 : Phase I , 3-way Crossover , Drug-drug Interaction Between TMC435350 Rifampin After Multiple Dosing .</brief_title>
	<detailed_description>This Phase I , open-label , randomize , 3-way crossover trial 18 healthy volunteer investigate potential drug-drug interaction rifampin TMC435350 . TMC435350 protease inhibitor development treatment chronic HCV infection . The goal ass PK safety data generate 3 in-patients session . At session volunteer receive one 3 treatment . Rifampin medication commonly give patient Mycobacterium infection tuberculosis . Some patient chronic HCV tuberculosis , therefore necessary know medication affect take together . Treatment A : TMC435350 200 mg q.d . 7 day . Treatment B : rifampin 600 mg q.d . 7 day . Treatment C : combination TMC435350 200 mg q.d . + rifampin 600 mg q.d . 7 day . There washout period least 10 day subsequent session . Day 8 treatment session first day washout period . Full pharmacokinetic profile TMC435350 determine Day 7 Treatments A C. Full pharmacokinetic profile rifampin active metabolite 25-deacetyl rifampin determine Day 7 Treatments B C. Safety tolerability monitor continuously throughout trial . Volunteers receive dose regimen Treatments A , B , C : Treatment A : TMC435350 200 mg q.d . 7 day . Treatment B : rifampin 600 mg q.d . 7 day , Treatment C : combination TMC435350 200 mg+rifampin 600 mg q.d . 7 day . The volunteer enter test facility night first dose session ( Day -1 = one day first dose ) stay test facility 72 hour last intake medication Day ( 10 ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Volunteers must meet follow inclusion criterion : Non smoke least 3 month prior selection , Normal weight define body mass index ( BMI , weight kg divide square height meter ) 18.0 32.0 kg/m2 , extremes include ) , Informed Consent Form ( ICF ) sign voluntarily first trial related activity , Able comply protocol requirement , Normal 12lead electrocardiogram ( ECG ) ( triplicate ) screen include : Normal sinus rhythm ( heart rate [ HR ] 40 100 bpm ) , QTc interval = 450 m , QRS interval &lt; 120 m , PR interval = 220 m Healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical history , vital sign , result blood biochemistry , hematology test urinalysis carry screening . Past history heart arrhythmia ( extrasystole , tachycardia rest ) baseline prolongation QTc interval &gt; 450 ms history risk factor Torsade de Pointes syndrome ( hypokalemia , family history long QT syndrome ) Female , except postmenopausal since 2 year , posthysterectomy , post tubal ligation ( without reversal operation ) History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use , investigator 's opinion would compromise subject 's safety and/or compliance trial procedure Hepatitis A , B , C infection ( confirm hepatitis A antibody , hepatitis B surface antigen , hepatitis C virus antibody , respectively ) human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection screen A positive urine drug test screen Currently active underlie gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease Currently significant diarrhea , gastric stasis , constipation investigator 's opinion could influence drug absorption bioavailability Any history significant skin disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>TMC435350-TiDP16-C105</keyword>
	<keyword>TMC435350-C105</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Rifampin</keyword>
</DOC>